T he central nervous system (CNS) is the most sophisticated organ of the human body-orchestrating vegetative, motor, and cognitive behaviors involved in daily living. This control center is equipped with a battery of protections against mechanical aggression, viral attacks, chemicals, and cerebrospinal fluid (CSF) leakage.
In both applications, e-dura exhibited reliable functionality over extended periods.
The translation of this technology into clinical implants faces a series of challenges. These hurdles notably include compliance of all the constituents with regulatory requirements, development of reliable implants for a duration of use that is compatible with human medical devices, and interface of e-dura with implantable stimulation and recording electronics. While we are tackling these technical challenges, we have imagined clinical applications wherein e-dura could be used by physicians to treat and alleviate neurologic deficits.
Meddling in the Spinal Cord Pain Therapies
Epidural electrical stimulation of the spinal cord has become a common medical practice to alleviate neuropathic pain resistant to classic therapies. 6 The electrical current elicits a pleasant sensation that blocks the brain's ability to perceive persistent pain sensations. This treatment allows patients to reduce analgesic medication use and thus improves their quality of life. The more severely affected patients with chronic intractable mechanical pain or pronounced spasticity benefit from the additional intrathecal delivery of morphine derivatives or spasmolytic drugs into the intrathecal space through a catheter attached to an implantable electronic pump. 7 The multimodal properties of e-dura support the delivery of electrical and pharmacologic neuromodulation therapies through the same medical device that establishes an intimate interface with spinal tissue. Compared with implants located above the dura mater, the location of the e-dura over the pia mater improves stimulation
Key Points
Question What are the advantages and possible applications of the soft, multimodal neural interface electronic dura mater?
Findings Soft neural interfaces limit chronic central nervous system inflammation and conform to the surface of the brain and spinal cord. In this preclinical review, the ability to stimulate and record from the same device was found to offer a range of clinical applications, especially when neuromodulation therapies need to be applied in poorly accessible regions or when the therapy can be titrated based on neural activity recordings.
Meaning
The soft neural interface electronic dura mater provides new therapeutic options to treat or alleviate neurologic disorders. A, Photograph of the e-dura implant tailored for spinal cord repair interventions. The silicone-based membrane combines soft electrodes and a microfluidic channel termed the chemotrode. Inset shows a close-up view of in situ drug delivery (droplet diameter, 2 mm). B, Cross-section of the subdural e-dura implant surgically inserted on the surface of the spinal cord 6 weeks after implantation. C, Reconstructed 3-dimensional microcomputed tomography scan of the e-dura implant in the spinal canal at 5 weeks after implantation. Adapted in part from Minev et al. specificity and allows a substantial decrease in the amount of current that is necessary to mediate therapeutic effects. 1 This feature enhances the life of the battery, supporting the development of more ecological pulse generators that may play a crucial role in augmenting the patient's acceptance of implanted devices. 8 Moreover, the chemotrode provides the opportunity to deliver morphine or baclofen through the same medical device, thus reducing the cost and complexity.
Improving Motor Control After Spinal Cord Injury
Spinal cord damage interrupts the communication between supraspinal centers and lumbar spinal circuits that produce leg movements. Albeit intact, lumbar spinal circuits lack the essential source of modulation and excitation originating from brainstem centers 9 to sustain walking. 10 Neuromodulation approaches have been developed to replace these missing inputs. For example, the combination of serotoninergic agonists and electrical stimulation of lumbar segments restored locomotion in rats with a complete injury.
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Electrical stimulation also reactivated lumbar spinal circuits in patients with paraplegia.
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These observations prompted us to study the interactions between this stimulation and spinal circuits for clinical applications. Previous studies 13, 14 found that the stimulation engages spinal circuits through the modulation of proprioceptive feedback circuits located in the dorsal roots. This framework guided the design of e-dura implants that integrated spatially selective electrodes. These electrodes target the dorsal roots projecting to spinal segments that contain the circuits that produce extension vs flexion movements.
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The e-dura implants were positioned subdurally, which enabled the concurrent delivery of electrical and chemical stimulation. 1 Realtime control of stimulation not only activated but also controlled the activity of spinal circuits engaging synergistic muscle groups. 5 Spatiotemporal neuromodulation therapies improved gait quality, endurance, and skilled locomotion. 5 These concepts are directly translatable to strategies to improve motor control in humans.
Meddling in the Brain
The management of neurogenic pain brings a flurry of challenges. Pharmacologic therapies often show limited efficacy. 7 Motor cortex stimulation delivered over the epidural surface has emerged as a potential strategy to treat resistant peripheral and central neurogenic pain resulting from stroke or trigeminal neuropathy. 15 Imaging studies 16 suggest that motor cortex stimulation inhibits the high firing rate of the sensory compartment of the thalamus and increases the activity of the cingulate gyrus, which together diminish pain. In present applications, electrodes are positioned epidurally. Compared with subdural electrode placement, this location prevents arachnoiditis and mitigates complications. However, this approach has 2 major drawbacks. First, brain atrophy increases the distance between electrodes and targeted cortical regions. Analgesic effects require larger electrical currents, which disrupt nontargeted regions and thus elicit adverse effects. Second, the interhemispheric region is not accessible from the epidural surface, which has restricted the application of motor cortex stimulation to the regions of the face and upper limbs. 17 The unique biomechanical properties of e-dura afford an intimate apposition of soft electrodes in the vicinity of cortical tissue while preventing inflammation or venous mechanical shearing lesions. Previous studies 18 described the advantages of subdural implants for motor cortex stimulation but also revealed higher complication rates. The insertion of e-dura in the interhemispheric region allows targeting of the leg area that is currently inaccessible with epidural stimulation while potentially reducing nondesired effects. For example, e-dura can be easily slid below the dura mater without damaging tissue or triggering foreign body reaction. 1 Stimulations revealed that e-dura moves together with neural tissue, which contributes to the long-term biointegration.
Novel Therapeutic Missions
The secret agent e-dura can be inserted below the dura mater incognito. This camouflaged programmable membrane can read from and write into the CNS through electrical and chemical communication channels. These features provide e-dura with a range of therapeutic missions. To understand this potential, we have identified the following 4 capacities in the fight against neurologic disorders:
(1) the scout, which explores conflict zones in the brain and provides this information to ground troops (ie, therapeutic agents to regulate brain activity); (2) the hacker, which extracts the patient's intention from neural signal decoding to control of a lost or an impaired function; (3) the firefighter, which extinguishes anarchic behaviors in the brain; and (4) the strategist, which acts for longer periods to reprogram brain functions ( Figure 2 ).
The Scout Deep brain stimulation (DBS) of the subthalamic nucleus is a common medical practice to alleviate motor and behavioral impairments associated with neurologic disorders such as Parkinson disease, dystonia, essential tremor, obsessive-compulsive disorder (OCD), or even depression. 19 More than 90 clinical trials have probed the ability of DBS to treat neurologic diseases. 19 Clinical studies showed that the stimulation variables not only differ between anatomical targets and therapeutic applications but also from patient to patient. Physicians tune the locations and variables of stimulation empirically based on visual observations. After titration, the patient has very limited control over stimulation features. The amount of injected energy is not adapted to the state of pathogenic circuits. 8 This approach fails to exploit the full potential of these interventions. Instead, closed-loop control systems based on detection of pathologic neural activity could titrate therapies to meet dynamic patient-specific needs. 20 For example, studies in patients with Parkinson disease have shown that motor impairments correlate with the subthalamic nucleus activity in the beta frequency band (13-30 Hz). The power of this band has been exploited to control the amount of delivered current. 21 This closed-loop control policy mediated superior motor improvements compared with continuous or random stimulation. Exaggerated coupling between the beta rhythm and the amplitude of broadband motor cortex activity is an alternative control signal for this application.
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These results provide a glimpse at the exciting future: a new era of precision neuroprosthetics. The one-size-fits-all DBS technology is on the track to obsolescence. Next-generation neuromodulation therapies could exploit e-dura implants that are tailored to the surface and geography of a targeted cortical region to record neural states. The e-dura implant is more pliable and better conforms to the gyri and sulci of the brain. This property is likely to enable intrasulcal electrocorticography with minimally invasive neurosurgi-cal protocols. 23 Such e-dura implants would act as scouts that survey circuitopathy to optimize stimulation variables that normalize neural states (Figure 2A ). This approach may translate to various neurologic and psychiatric disorders. For example, OCD affects 2% to 3% of the population. People with OCD exhibit recurrent intrusive thoughts (obsessions), repetitive behaviors, and/or mental acts (compulsions) triggered by anxiety. Obsessive-compulsive disorder was initially linked to altered corticostriatal circuitry, but recent neuroimaging studies 24 uncovered networks of interlinked neuronal systems in patients with OCD. The emergence of symptoms has been associated with excessive prefrontal activity. 24 Nucleus accumbens DBS is a possible strategy to alleviate medically resistant OCD. 19 The nucleus accumbens interfaces the limbic and motor systems. The stimulation thus aims at regulating the disrupted integration of emotional and motor information in the nucleus accumbens. At present, the stimulation is delivered continuously. A potentially more efficacious strategy may exploit e-dura implants to detect abnormal neuronal activity from prefrontal recordings and trigger nucleus accumbens DBS on demand to diminish the amplitude or even prevent the onset of compulsions and obsessions.
The Hacker
The e-dura implants could help the brain deliver commands to disrupted circuits or paralyzed limb muscles. Similar to a hacker meddling in a computer program to take control of its operations ( Figure 2B ), e-dura can crack the neural code to detect motor intentions.
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The e-dura implant can be positioned over the leg region of the motor cortex, which is located in the interhemispheric fissure. This location is difficult to access using rigid implants. Leg motor cortex signals allow decoding of gait initiation or gait timing, 1 which provides high-level commands to steer locomotor prosthetics. 26 This decoding may directly adjust spinal cord stimulation to reestablish leg movements after paralysis. 27 When implanted over the arm motor cortex region, e-dura could support the design of a braincomputer interface that links intended hand movements to computers, prosthetic limbs, or arm muscle stimulation.
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The Firefighter
The e-dura implant could serve as a firefighter that extinguishes anarchic brain behaviors, such as epileptic seizure ( Figure 2C ). Although this neurologic disorder is generally well controlled with medication, epilepsy is refractory to pharmacotherapy in 20% to 30% of patients. When medically intractable seizures emerge from a welldefined, noneloquent region, ablative surgery of the epileptic focus provides an efficient strategy to treat these patients. Neuromodulation therapies, including vagal nerve stimulation or thalamic DBS, are the only alternative strategies for patients who are not candidates for ablative surgery. 
S p e e ch S p e e c h
The e-dura implant (cyan) can read from and write into the central nervous system using electrodes and chemotrodes (purple) to treat neurologic disorders. As the scout, e-dura reads the neural state to adjust deep brain stimulation therapies to the current need of the patient. As the hacker, e-dura reads motor intention from cortical ensemble modulation (illustrated for hand movement). As the firefighter, e-dura detects the onset of an epileptic episode and delivers electrical and chemical stimulation to extinguish the seizure. As the strategist, e-dura delivers stimulation over an eloquent region of the brain to encourage adjacent regions to take over its function, thus allowing the preservation of speech abilities after removal of the brain tumor in the targeted region.
Electronic Recently, NeuroPace received a premarket approval from the US Food and Drug Administration for a closed-loop device that controls medically refectory seizures. This device integrates leads targeting the surface of the cortex and deep structures overlying the preidentified epileptic foci. The NeuroPace system automatically senses abnormal neural activity and responds to emerging seizures with electrical shocks that stop the seizure. A double-blind randomized clinical trial 30 reported that NeuroPace decreased mean seizure frequency by 37.9%. A reduction of the delay between seizure detection and electric shock delivery could enhance the efficacy of this treatment. Indeed, the key feature of this strategy is to trigger the electric shock before the spread of the epileptic wave. The e-dura implants present several advantages in this firefight. This membrane can cover a large cortical surface, integrate dozens of electrodes to provide high-level territory surveillance, and fire electrical shocks over multiple regions simultaneously or sequentially. However, this type of implant will require multichannel connectors, amplifiers, and other complex electronics that are still under development. 31 Moreover, e-dura the firefighter can integrate a second line of defense. The microfluidic channels enable the rapid infusion of antiepileptic drugs at the specific sites of fire. For example, the local cortical infusion of γ-aminobutyric acid agonists has mediated anticonvulsive effects in animal models of epilepsy. 32 The local application allows the drug to reach a high concentration at the target site, while minimizing the secondary adverse effects associated with systemic administration.
The Strategist
A sudden neurologic insult opens a window of opportunity for neuroplasticity, which mediates partial recovery of affected bodily functions. Consequently, the development of strategies to augment neuroplasticity remains a major challenge and priority in public health policies. Neuromodulation therapies showed the ability to promote anatomical and structural reorganization of neural pathways. For example, long-lasting stimulation of corticospinal axons after spinal cord injury triggered a sprouting of synaptic terminals in the brainstem and spinal cord. 33, 34 This remodeling enhanced motor recovery in animal models. Similarly, repetitive transcranial magnetic stimulation and transcranial direct current stimulation enhanced motor learning and cognitive recovery in persons with stroke.
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These treatments use noninvasive techniques that not only lack specificity but also require specialists who deliver the stimulation during succinct sessions scattered across several weeks. The strategist properties of e-dura are uniquely fitted to improve these approaches. The implantation of e-dura over targeted cortical regions enables delivery of long-term stimulation, which is likely to lead to more pronounced improvements compared with intermittent stimulations. Moreover, the practicality of implantable technology enhances the spectrum of possible combinatorial therapies. Electrical stimulation patterns can be synchronized with virtual reality environments, robotic actuation, and sensory enhancement to augment the cognitive, motor, and sensory rehabilitation experience. The rapid development of bioresorbable electronics 37 may even offer the additional advantage of limiting this strategy to a single surgical intervention.
Removal of a glioma from a dominant cerebral hemisphere may endanger critical brain functions, including the understanding and production of language. Aggressive gliomas lead to irreversible loss of functions encoded in the invaded region. Instead, longitudinal neuroimaging studies revealed that, when gliomas grow slowly, surrounding brain territories progressively take over the operations of invaded regions, which results in unexpected preservation of function. On one hand, this vicarious potential of surrounding brain tissues conflicts with the primary strategy of neurosurgeons, which consists of maximizing total gross tumor resection. On the other hand, this neuroplasticity can be exploited to preserve functions. This awareness has triggered the development of staged surgical treatments whereby gliomas are removed during awake surgery until approaching eloquent areas. A second surgical resection is performed several months later when neuroplasticity has occurred in surrounding tissues.
In the ideal scenario, the neurosurgeon would implant a neuromodulation device during the first resection to accelerate the shift of the eloquent area and thus reduce the interval between the ablation procedures. In the strategist application, e-dura could empower neurosurgeons with the weapon to make this strategy a reality ( Figure 2D) . A case study reported that high-frequency stimulation applied for 25 days over the surface of a partially resected tumor located in the Broca area produced a mild speech disturbance that forced the brain to shift the location of the speech area away from the stimulation. 38 Therefore, shortly after the first partial resection, a second, more radical resection could be performed without altering the speech abilities of the patient. The versatility of e-dura implants is well suited for this application. Moreover, e-dura provides the opportunity to infuse chemotherapies locally to reduce the growth of the tumor.
Conclusions
We sought to provide a glimpse of the exciting therapeutic opportunities that next-generation implant technology, such as e-dura, may provide for the diagnosis and treatment of neurologic disorders. This technology heralds precision neuroprosthetics. Although challenges lie ahead to pass the various regulatory hurdles and technical issues along the path to clinical fruition, we believe that the pluripotent secret agent e-dura will provide a novel arsenal to help neurologists and neurosurgeons meddle in the intimate and hidden territories of the brain and spinal cord to treat or alleviate neurologic deficits and thus improve a patient's quality of life.
